Counterfeit products must be identified and removed from the marketplace, and a regulatory partnership between governments, the pharmaceutical sector, and citizens’ groups must be developed to control for quality.
As diretrizes de tratamento devem incorporar estas informações e ser transmitidas a todos os fornecedores de antibióticos.